Severity grading system for acute allergic reactions: A multidisciplinary Delphi study.


Journal

The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002

Informations de publication

Date de publication:
07 2021
Historique:
received: 29 09 2020
revised: 29 12 2020
accepted: 08 01 2021
pubmed: 22 1 2021
medline: 13 10 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

There is no widely adopted severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions, thus limiting the ability to optimize and standardize management practices and advance research. The aim of this study was to develop a severity grading system for acute allergic reactions for use in clinical care and research. From May to September 2020, we convened a 21-member multidisciplinary panel of allergy and emergency care experts; 9 members formed a writing group to critically appraise and assess the strengths and limitations of prior severity grading systems and develop the structure and content for an optimal severity grading system. The entire study panel then revised the grading system and sought consensus by utilizing Delphi methodology. The writing group recommended that an optimal grading system encompass the severity of acute allergic reactions on a continuum from mild allergic reactions to anaphylactic shock. Additionally, the severity grading system must be able to discriminate between clinically important differences in reaction severity to be relevant in research while also being intuitive and straightforward to apply in clinical care. Consensus was reached for all elements of the proposed severity grading system. We developed a consensus severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions. Successful international validation, refinement, dissemination, and application of the grading system will improve communication among providers and patients about the severity of allergic reactions and will help advance future research.

Sections du résumé

BACKGROUND
There is no widely adopted severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions, thus limiting the ability to optimize and standardize management practices and advance research.
OBJECTIVE
The aim of this study was to develop a severity grading system for acute allergic reactions for use in clinical care and research.
METHODS
From May to September 2020, we convened a 21-member multidisciplinary panel of allergy and emergency care experts; 9 members formed a writing group to critically appraise and assess the strengths and limitations of prior severity grading systems and develop the structure and content for an optimal severity grading system. The entire study panel then revised the grading system and sought consensus by utilizing Delphi methodology.
RESULTS
The writing group recommended that an optimal grading system encompass the severity of acute allergic reactions on a continuum from mild allergic reactions to anaphylactic shock. Additionally, the severity grading system must be able to discriminate between clinically important differences in reaction severity to be relevant in research while also being intuitive and straightforward to apply in clinical care. Consensus was reached for all elements of the proposed severity grading system.
CONCLUSION
We developed a consensus severity grading system for acute allergic reactions, including anaphylactic and nonanaphylactic reactions. Successful international validation, refinement, dissemination, and application of the grading system will improve communication among providers and patients about the severity of allergic reactions and will help advance future research.

Identifiants

pubmed: 33476673
pii: S0091-6749(21)00047-6
doi: 10.1016/j.jaci.2021.01.003
pmc: PMC8273088
mid: NIHMS1682583
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

173-181

Subventions

Organisme : AHRQ HHS
ID : K08 HS026503
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Références

N Engl J Med. 1992 Aug 6;327(6):380-4
pubmed: 1294076
Allergy. 2018 Sep;73(9):1792-1800
pubmed: 29331045
J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):58-62.e5
pubmed: 28065342
J Allergy Clin Immunol. 2017 Sep;140(3):750-758.e15
pubmed: 28342911
Ann Allergy Asthma Immunol. 2007 Mar;98(3):252-7
pubmed: 17378256
J Allergy Clin Immunol. 2007 Apr;119(4):1016-8
pubmed: 17306354
J Allergy Clin Immunol. 2013 Nov;132(5):1141-1149.e5
pubmed: 23915715
J Allergy Clin Immunol Pract. 2021 Jan;9(1):311-320.e2
pubmed: 33217612
JAMA. 2016 Feb 23;315(8):775-87
pubmed: 26903336
Pediatr Crit Care Med. 2005 Jan;6(1):2-8
pubmed: 15636651
N Engl J Med. 2018 Nov 22;379(21):1991-2001
pubmed: 30449234
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
N Engl J Med. 2003 Mar 13;348(11):986-93
pubmed: 12637608
J Allergy Clin Immunol. 2009 Oct;124(4):786-92.e4
pubmed: 19767073
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
J Allergy Clin Immunol Pract. 2019 Apr;7(4):1148-1156.e5
pubmed: 30737191
Am J Respir Crit Care Med. 2017 Aug 15;196(4):425-429
pubmed: 28240961
Pediatrics. 2003 Jun;111(6 Pt 3):1601-8
pubmed: 12777599
N Engl J Med. 2015 Feb 26;372(9):803-13
pubmed: 25705822
J Allergy Clin Immunol. 2004 Aug;114(2):371-6
pubmed: 15316518
Front Public Health. 2018 Jun 11;6:149
pubmed: 29942800
Allergy Asthma Immunol Res. 2015 Jan;7(1):22-9
pubmed: 25553259
J Allergy Clin Immunol. 2020 Apr;145(4):1082-1123
pubmed: 32001253
Stroke. 1989 Jul;20(7):864-70
pubmed: 2749846
World Allergy Organ J. 2019 Oct 31;12(10):100066
pubmed: 31719946
J Allergy Clin Immunol. 2008 Mar;121(3):632-638.e2
pubmed: 18207562
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
J Allergy Clin Immunol. 2006 Feb;117(2):391-7
pubmed: 16461139
J Allergy Clin Immunol. 2010 Mar;125(3):569-74, 574.e1-574.e7
pubmed: 20144472
J Allergy Clin Immunol Pract. 2020 Feb;8(2):767-768.e2
pubmed: 31466851
Otolaryngol Head Neck Surg. 1999 Sep;121(3):263-8
pubmed: 10471868
J Allergy Clin Immunol. 2012 Dec;130(6):1260-74
pubmed: 23195525
Allergy. 2016 Feb;71(2):135-6
pubmed: 26381421
Lancet Gastroenterol Hepatol. 2018 Feb;3(2):85-94
pubmed: 29242014
N Engl J Med. 2012 Jul 19;367(3):233-43
pubmed: 22808958
J Allergy Clin Immunol. 2020 Nov;146(5):1089-1096
pubmed: 32853640
Ann Allergy Asthma Immunol. 2019 Apr;122(4):373-380.e1
pubmed: 30703439

Auteurs

Timothy E Dribin (TE)

Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio. Electronic address: Timothy.Dribin@cchmc.org.

David Schnadower (D)

Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio.

Jonathan M Spergel (JM)

Division of Allergy and Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa.

Ronna L Campbell (RL)

Department of Emergency Medicine, Mayo Clinic, Rochester, Minn.

Marcus Shaker (M)

Dartmouth Geisel School of Medicine, Hanover, NH; Dartmouth-Hitchcock Medical Center, Hanover, NH.

Mark I Neuman (MI)

Division of Emergency Medicine, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass.

Kenneth A Michelson (KA)

Division of Emergency Medicine, Boston Children's Hospital, Boston, Mass; Department of Pediatrics, Harvard Medical School, Boston, Mass.

Peter S Capucilli (PS)

Rochester Regional Health, Rochester, NY.

Carlos A Camargo (CA)

Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

David C Brousseau (DC)

Section of Pediatric Emergency Medicine, Department of Pediatrics, Medical College of Wisconsin, Milwaukee.

Susan A Rudders (SA)

Department of Pediatrics, Harvard Medical School, Boston, Mass; Division of Immunology, Boston Children's Hospital, Boston, Mass.

Amal H Assa'ad (AH)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Kimberly A Risma (KA)

Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio; Division of Allergy and Immunology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Mariana Castells (M)

Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

Lynda C Schneider (LC)

Department of Pediatrics, Harvard Medical School, Boston, Mass; Division of Immunology, Boston Children's Hospital, Boston, Mass.

Julie Wang (J)

Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.

Juhee Lee (J)

Division of Allergy and Immunology, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pa.

Rakesh D Mistry (RD)

Section of Emergency Medicine, Department of Pediatrics, Children's Hospital Colorado, Aurora.

David Vyles (D)

Section of Pediatric Emergency Medicine, Department of Pediatrics, Medical College of Wisconsin, Milwaukee.

Michael Pistiner (M)

Department of Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

John K Witry (JK)

Division of Emergency Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Yin Zhang (Y)

Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.

Hugh A Sampson (HA)

Division of Allergy and Immunology, Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH